Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel

Autor:	Fizazi, Karim Jones, Robert Oudard, Stephane Efstathiou, Eleni Saad, Fred De Wit, Ronald De Bono, Johann Sebastian and Cruz, Felipe Fountzilas, George Ulys, Albertas Carcano, Flavio Agarwal, Neeraj Agus, David B. Bellmunt, Joaquim and Petrylak, Daniel Peter Lee, Connie Tejura, Bindu Borgstein, Niels Geert Dreicer, Robert
Jazyk:	angličtina
Rok vydání:	2014
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=od______2127::14adbfd928bce4a0909b7704fd41d867 https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3161793 Zobrazit plný text záznamu